GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Getinge has a strong market share in India within several product segments
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Subscribe To Our Newsletter & Stay Updated